The Paradigm of Pharma Manufacturing is Shifting

Modern medicine is stepping into an exciting and promising renaissance with a wave of small-batch cell, gene and curative therapies receiving regulatory approvals. Sixteen months ago, it was Luxturna, an eye disease treatment from Spark Therapeutics. A few weeks ago, Novartis announced the world’s most costly treatment to date: Zolgensma for Spinal Muscular Atrophy. Then […]